| Patient | Ronald Reagan |
|---|---|
| Date of birth | 1936-02-06 |
| Identifiers | MRN HR-ML008-SYN; SSN (made up) 000-08-6047 |
| Document date | 2026-07-14 |
| Author | Margaret Ellison, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Six-month post-fracture, dementia, and caregiver review. [S]
Mr. Reagan returns six months after the repair of his right hip fracture. He has had no falls. Home physical therapy finished last month, and he keeps up the home exercise program with supervision. He walks in the house and garden every day with the walker. He had no aches or fever after the zoledronic acid infusion three months ago. The evening restlessness is mild and unchanged. Weekly respite, the home health aide, and caregiver education continue, and the caregiver burden score has fallen. [S]
| Element | Detail |
|---|---|
| Interval change | Home therapy finished; daily walks with the walker; home exercise program |
| Falls | None since the fracture |
| Infusion tolerance | No flu-like reaction after zoledronic acid |
| Behavior | Mild evening restlessness, unchanged |
| Function | Barthel Index 85; Timed Up and Go 16 seconds |
| Caregiver | Zarit Burden Interview 27 of 88, down from 41 |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Weight stable; appetite good; no fever |
| Cardiovascular | Negative | No lightheadedness on standing or fainting |
| Musculoskeletal | Negative | No hip, thigh, or back pain |
| Neurological | Positive | Known memory loss, unchanged by his caregivers' account |
| Psychiatric | Positive | Mild evening restlessness; no low mood; GDS-15 score 3 |
5 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Donepezil 10 mg oral tablet, one tablet by mouth daily in the morning | One tablet by mouth daily in the morning | Oral route | 2022-03-07 | active | S |
| Acetaminophen 500 mg oral tablet, two tablets (1,000 mg) by mouth three times daily | Two tablets by mouth three times daily | Oral route | 2026-01-14 to 2026-04-14 | completed | S |
| Oxycodone 5 mg oral tablet, one tablet by mouth every six hours as needed for severe pain | One tablet by mouth every six hours as needed for severe pain | Oral route | 2026-01-14 to 2026-02-10 | stopped | S |
| Diphenhydramine 25 mg oral capsule, one capsule by mouth at bedtime | One capsule by mouth at bedtime | Oral route | 2026-01-16 to 2026-02-10 | stopped | S |
| Enoxaparin 40 mg/0.4 mL prefilled syringe, inject 40 mg under the skin daily through day 35 after surgery | Inject 40 mg under the skin once daily | Subcutaneous route | 2026-01-14 to 2026-02-17 | completed | S |
| Cholecalciferol 50 mcg (2,000 units) oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2026-02-10 | active | S |
| Zoledronic acid 5 mg/100 mL intravenous infusion over at least 15 minutes, once yearly | 5 mg intravenously over at least 15 minutes once a year; first dose given | Intravenous route | 2026-04-14 to 2026-04-14 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-07-14 | Body height | 185 | cm | S |
| 2026-07-14 | Body weight | 78 | kg | S |
| 2026-07-14 | Body mass index (BMI) [Ratio] | 22.8 | kg/m2 | S |
| 2026-07-14 | Systolic blood pressure | 128 | mm[Hg] | S |
| 2026-07-14 | Diastolic blood pressure | 70 | mm[Hg] | S |
| 2026-07-14 | Heart rate | 64 | /min | S |
| 2026-07-14 | Respiratory rate | 16 | /min | S |
| 2026-07-14 | Body temperature | 36.7 | Cel | S |
| 2026-07-14 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-07-14 | Calcium [Mass/volume] in Serum or Plasma | 9.4 | mg/dL | 8.6-10.3 mg/dL | Normal | S |
| 2026-07-14 | Hemoglobin [Mass/volume] in Blood | 13.7 | g/dL | 13.2-16.6 g/dL | Normal | S |
| 2026-07-14 | Total score Barthel Index | 85 | {score} | S | ||
| 2026-07-14 | Geriatric depression scale (GDS) short version total | 3 | {score} | S |
Vital signs recorded on 2026-07-14; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Alert, cheerful, and sociable |
| Cardiovascular | Regular rhythm at 64 per minute; no edema; no fall in blood pressure on standing |
| Musculoskeletal | Right hip incision well healed; painless hip movement; Timed Up and Go 16 seconds with the walker, down from 24 at the first visit |
| Neurological | Oriented to person, not to date; no focal weakness |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Alzheimer's disease with late onset, disclosed in 1994 | active | confirmed | G30.1 | S — Synthetic modern coding of the publicly disclosed diagnosis. |
| Dementia due to Alzheimer's disease, moderate (FAST stage 5), with evening restlessness | active | confirmed | F02.B0 | S — Synthetic stage; his actual stage at this age was not made public. |
| Osteoporosis with right hip fragility fracture after a fall at home, repaired with internal fixation; subsequent care | active | confirmed | M80.051D | S — Synthetic modern coding of the documented January 2001 hip fracture as an osteoporotic fracture; bone density and fracture pattern are synthetic. |
| Vitamin D deficiency | resolved | confirmed | E55.9 | S — Synthetic finding from the first-visit 25-hydroxyvitamin D; repleted by three months. |
| Acute blood loss anemia after hip surgery | resolved | confirmed | D62 | S — Synthetic postoperative finding; resolved by three months. |
| History of falling | active | confirmed | Z91.81 | S — Synthetic modern coding linked to the documented fall. |
| Personal history of colon cancer, operated on in 1985 | active | confirmed | Z85.038 | S — Synthetic modern coding of the documented 1985 operation. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Serum calcium after the first zoledronic acid infusion | Before each dose; checked once after the first | Completed today | 9.4 mg/dL; no low calcium after the infusion |
| Laboratory | Hemoglobin | Follow-up of postoperative anemia | Completed today | 13.7 g/dL; anemia resolved |
| Laboratory | Calcium, phosphorus, and kidney function before the second infusion | Before each intravenous dose | Due | In about nine months; phosphorus added after the gap noted at three months |
| Laboratory | 25-hydroxyvitamin D | Yearly after repletion | Up to date | 36 ng/mL three months ago; next in about nine months |
| Imaging | DXA | Every 1 to 3 years on therapy | Up to date | Baseline three months ago |
| Imaging | Vertebral fracture assessment | At baseline after a low-trauma fracture or with a T-score of -2.5 or lower | Due | Missed at the three-month DXA. Height still 185 cm and no back pain; planned with the next DXA |
| Examination | Timed Up and Go | When home therapy ends, then yearly or with a change | Completed today | 16 seconds with the walker, down from 24; above the 12-second threshold |
| Examination | CDC STEADI fall-risk screen: fall history, gait and balance, postural blood pressure | Every primary care visit after the fracture | Completed today | No falls; no fall in blood pressure on standing |
| Examination | Pain assessment | Every visit | Completed today | No pain |
| Examination | Physical and occupational therapy progress | Every visit | Completed today | Barthel Index 85; home therapy finished; home exercise program continues |
| Examination | Home safety evaluation | At diagnosis and each follow-up | Completed today | Home safety changes in place; supervision at night |
| Medication safety | AGS Beers Criteria medication review | Every visit and at each transition of care | Completed today | Donepezil and cholecalciferol only; no Beers-listed medicine |
| Medication safety | Cholinesterase inhibitor benefit and tolerability | Each follow-up | Completed today | Heart rate 64; no fainting; continue |
| Medication safety | Zoledronic acid tolerance | After each infusion | Completed today | No acute-phase reaction; no thigh pain |
| Survey | Neuropsychiatric symptom screen (NPI-Q) | Every visit | Completed today | Mild evening restlessness, unchanged |
| Survey | Depression screen (GDS-15) | At 1, 3, and 6 months after the fracture; yearly in dementia | Completed today | Score 3, below the threshold of 5 |
| Survey | Caregiver assessment with the Zarit Burden Interview | At diagnosis, then every 6 to 12 months | Completed today | 27 of 88, down from 41 |
| Survey | Cognitive test (MoCA), FAST stage, and ADL and IADL scores | At diagnosis, then yearly | Up to date | Next at the yearly dementia review in about seven months |
| Survey | FRAX 10-year fracture risk | After the fracture and with each DXA | Due | Not calculated at the three-month DXA; planned with the next DXA |
| Referral | Caregiver support services | Ongoing | Completed today | Weekly respite, home health aide, and caregiver education continue |
| Self-management | Exercise program | Ongoing | Completed today | Home exercise program and daily supervised walks |
| Self-management | Advance care planning | At diagnosis, yearly, and at stage changes | Up to date | POLST completed three months ago; revisit at any change in stage |
| Self-management | Calcium intake from food and supplements | Ongoing; target 1,000 to 1,200 mg a day | Completed today | Calcium-rich food at each meal |
Goal progress:
Guideline basis: Management of Hip Fractures in Older Adults Evidence-Based Clinical Practice Guideline (2021); The clinician's guide to prevention and treatment of osteoporosis (2022); American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults (2023); Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD-ADRD) (2024); CMID: Clinical Monitoring Intelligence Database, Alzheimer's disease, hip/pelvic fracture, and osteoporosis monographs (2026); Falls Prevention in Community-Dwelling Older Adults: Interventions (2024)
Follow-up: Annual wellness visit in three months. Yearly dementia review in about seven months. Calcium, phosphorus, and kidney function before the second zoledronic acid infusion in about nine months. Next scheduled visit 2026-10-13: subsequent annual wellness visit. [S]